The epigenetics of breast cancer – Opportunities for diagnostics, risk stratification and therapy
Abstract: The stage and molecular pathology-dependent prognosis of breast cancer, the limited treatment options for triple-negative carcinomas, as well as the development of resistance to therapies illustrate the need for improved early diagnosis and the development of new therapeutic approaches. Increasing data suggests that some answers to these challenges could be found in the area of epigenetics. In this study, we focus on the current research of the epigenetics of breast cancer, especially on the potential of epigenetics for clinical application in diagnostics, risk stratification and therapy. The differential DNA methylation status of specific gene regions has been used in the past to differentiate breast cancer cells from normal tissue. New technologies as detection of circulating nucleic acids including microRNAs to early detect breast cancer are emerging. Pattern of DNA methylation and expression of histone-modifying enzymes have been successfully used for risk stratification. However, all these epigenetic biomarkers should be validated in larger clinical studies. Recent preclinical and clinical studies show a therapeutic benefit of epigenetically active drugs for breast cancer entities that are still difficult to treat (triple negative, UICC stage IV). Remarkably, epigenetic therapies combined with chemotherapies or hormone-based therapies represent the most promising strategy. At the current stage, the integration of epigenetic substances into established breast cancer therapy protocols seems to hold the greatest potential for a clinical application of epigenetic research
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Epigenetics. - 17, 6 (2022) , 612-624, ISSN: 1559-2308
- Event
-
Veröffentlichung
- (where)
-
Freiburg
- (who)
-
Universität
- (when)
-
2021
- DOI
-
10.1080/15592294.2021.1940644
- URN
-
urn:nbn:de:bsz:25-freidok-2195230
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:49 PM CET
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
Time of origin
- 2021
Other Objects (12)
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Epigenetic therapy of cancer : preclinical models and treatment approaches
DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie
Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS
Epigenetics in pancreatic ductal adenocarcinoma: Impact on biology and utilization in diagnostics and treatment
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Epigenetic therapy of cancer : preclinical models and treatment approaches
DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie
Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS
Epigenetics in pancreatic ductal adenocarcinoma: Impact on biology and utilization in diagnostics and treatment
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Molekulare Mechanismen der normalen myeloischen Differenzierung und ihrer Störung bei akuten myeloischen Leukämien
MDS und akute myeloische Leukämie : ein biologisches und therapeutisches Kontinuum
Myelodysplastic syndromes and acute myeloid leukemia : a biological and therapeutic continuum
Epigenetic therapy of cancer : preclinical models and treatment approaches
DNA-Methylierungssignaturen bei älteren Patienten mit akuter myeloischer Leukämie
Charakterisierung der antileukämischen Aktivität von drei Hydroxamat-Histondesacetylase-Inhibitoren
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification - an approach to classification of patients with t-MDS
Epigenetics in pancreatic ductal adenocarcinoma: Impact on biology and utilization in diagnostics and treatment
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Elucidation of a hypersplicing phenotype in SRSF2 mutant myeloid malignancy